What is Eloxx Pharmaceut's earnings per share (EPS)?

Eloxx Pharmaceut (ELOX) reported diluted earnings per share of $-5.34 for fiscal year 2025. This represents a 42.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Eloxx Pharmaceut Financials

ELOX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Eloxx Pharmaceut (ELOX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 27 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELOX FY2025 2026-05-05

External financing is carrying a cash-burning business whose remaining obligations sit in short-term liabilities rather than debt.

The key improvement in FY2025 is that cash was rebuilt by financing, not operations: financing cash flow of $11.0M more than offset operating cash use of -$6.3M, so the higher cash balance does not reflect self-funding. Even with that refill, the working-capital position only improved from 0.1x to 0.3x, meaning near-term obligations still outweigh near-term resources by a wide margin.

Balance-sheet strain eased, with total liabilities falling from $27.3M to $17.2M. But liabilities remain overwhelmingly short-term and long-term debt is zero, so the company’s pressure point is day-to-day liquidity and refinancing access rather than term-debt servicing.

The expense base has been dramatically resized: SG&A fell from $10.7M to $3.4M. R&D also dropped from $23.7M to $3.1M, indicating the narrower loss reflects a much smaller operating footprint, and the current cost structure looks more like conservation than expansion.

Financial Health Signals

Financial health score pending refresh

We are recalculating Eloxx Pharmaceut's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-85.15

Eloxx Pharmaceut scores -85.15, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($41.2M) relative to total liabilities ($17.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Eloxx Pharmaceut passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

1.06x

For every $1 of reported earnings, Eloxx Pharmaceut generates $1.06 in operating cash flow (-$6.3M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Eloxx Pharmaceut generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$6.4M

YoY-164.6%

Eloxx Pharmaceut's EBITDA was -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 164.6% from the prior year.

Net Income

-$6.0M

YoY-90.7%

Eloxx Pharmaceut reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 90.7% from the prior year.

EPS (Diluted)

$-5.34

YoY+42.0%

Eloxx Pharmaceut earned $-5.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 42.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.8M

YoY+4210.8%

5Y CAGR-28.0%

10Y CAGR+13.3%

Eloxx Pharmaceut held $4.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

435,432

YoY+35.5%

Eloxx Pharmaceut had 435,432 shares outstanding in fiscal year 2025. This represents an increase of 35.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$3.1M

YoY-14.6%

5Y CAGR-26.8%

10Y CAGR-6.3%

Eloxx Pharmaceut invested $3.1M in research and development in fiscal year 2025. This represents a decrease of 14.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ELOX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$6.4M	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.1M-14.6%	$3.6M	N/A	$23.7M+3.6%	$22.9M+56.9%	$14.6M
SG&A Expenses	$3.4M-35.6%	$5.3M	N/A	$10.7M-47.7%	$20.4M+37.7%	$14.8M
Operating Income	-$6.4M-160.9%	-$2.5M	N/A	-$34.4M+47.9%	-$66.0M-97.3%	-$33.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$6.0M-90.7%	-$3.1M	N/A	-$36.1M+46.0%	-$66.7M-93.0%	-$34.6M
EPS (Diluted)	$-5.34+42.0%	$-9.20+87.4%	$-72.98	$-16.65+56.4%	$-38.15	N/A

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q4'23	Q3'23	Q2'23	Q1'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.7M	N/A	$510K	N/A	N/A	$1.3M-46.5%	$2.3M-33.0%	$3.5M
SG&A Expenses	$2.1M	N/A	$712K	N/A	N/A	$2.4M+32.5%	$1.8M-9.7%	$2.0M
Operating Income	-$3.8M	N/A	-$1.2M	N/A	N/A	-$3.6M+12.1%	-$4.1M+24.5%	-$5.5M
Interest Expense	$100K	N/A	$500K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.8M	N/A	-$1.7M	N/A	N/A	-$3.6M+17.3%	-$4.3M+30.3%	-$6.2M
EPS (Diluted)	$-0.86	N/A	$-4.94	N/A	N/A	$-1.31+33.2%	$-1.96+31.9%	$-2.88

ELOX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.3M+77.1%	$3.0M+73.8%	$1.7M-91.9%	$21.1M-53.2%	$45.1M+70.5%	$26.5M
Current Assets	$5.3M+77.1%	$3.0M+92.2%	$1.5M-92.3%	$20.1M-53.7%	$43.5M+67.9%	$25.9M
Cash & Equivalents	$4.8M+4210.8%	$111K-90.2%	$1.1M-94.1%	$19.2M-54.6%	$42.3M+71.3%	$24.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$17.2M-37.1%	$27.3M+12.3%	$24.3M-23.5%	$31.8M+39.7%	$22.8M+40.1%	$16.2M
Current Liabilities	$17.2M-37.1%	$27.3M+20.3%	$22.7M-1.7%	$23.1M+132.0%	$10.0M+1.2%	$9.8M
Long-Term Debt	$0	$0-100.0%	$1.6M-81.2%	$8.6M-28.7%	$12.0M+88.1%	$6.4M
Total Equity	-$11.9M+51.1%	-$24.3M-7.7%	-$22.6M-112.0%	-$10.7M-147.6%	$22.4M+118.8%	$10.2M
Retained Earnings	-$300.6M-2.0%	-$294.6M-1.1%	-$291.4M-6.2%	-$274.4M-15.1%	-$238.3M-38.9%	-$171.6M

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q4'23	Q3'23	Q2'23	Q1'23
Total Assets	$8.5M+61.3%	$5.3M	N/A	$3.0M+73.8%	$1.7M-71.7%	$6.0M+0.8%	$6.0M-16.8%	$7.2M
Current Assets	$8.5M+61.3%	$5.3M	N/A	$3.0M+92.2%	$1.5M-72.5%	$5.6M+4.6%	$5.4M-15.9%	$6.4M
Cash & Equivalents	$6.4M+33.0%	$4.8M+963.3%	$450K+305.4%	$111K-90.2%	$1.1M-76.3%	$4.8M+10.3%	$4.3M-11.7%	$4.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.1M-6.3%	$17.2M	N/A	$27.3M+12.3%	$24.3M-6.8%	$26.1M+6.1%	$24.6M+370.4%	-$9.1M
Current Liabilities	$16.1M-6.3%	$17.2M	N/A	$27.3M+20.3%	$22.7M-3.3%	$23.5M+10.4%	$21.3M+9.2%	$19.5M
Long-Term Debt	N/A	$0	N/A	$0-100.0%	$1.6M-38.5%	$2.6M-21.4%	$3.3M-17.2%	$4.0M
Total Equity	-$7.6M+36.3%	-$11.9M+54.2%	-$26.0M-6.9%	-$24.3M-7.7%	-$22.6M-12.7%	-$20.0M-7.8%	-$18.6M-214.1%	$16.3M
Retained Earnings	-$304.3M-1.2%	-$300.6M	N/A	-$294.6M-1.1%	-$291.4M-1.0%	-$288.6M-1.3%	-$285.0M-1.5%	-$280.6M

ELOX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.3M-34.2%	-$4.7M	N/A	-$31.8M+9.0%	-$35.0M-24.3%	-$28.2M
Capital Expenditures	N/A	N/A	N/A	$66K-25.8%	$89K	N/A
Free Cash Flow	N/A	N/A	N/A	-$31.9M+9.1%	-$35.1M	N/A
Investing Cash Flow	$1K-97.4%	$38K-87.7%	$309K+568.2%	-$66K-103.2%	$2.1M-93.9%	$33.8M
Financing Cash Flow	$11.0M+219.9%	$3.4M+184.2%	-$4.1M-146.3%	$8.8M-82.6%	$50.8M+1577.3%	-$3.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q4'23	Q3'23	Q2'23	Q1'23
Operating Cash Flow	-$5.5M	N/A	$1.2M	N/A	-$2.0M+41.7%	-$3.5M-67.0%	-$2.1M+69.7%	-$6.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$3.5M-67.0%	-$2.1M+69.7%	-$6.8M
Investing Cash Flow	N/A	N/A	N/A	N/A	$51K-78.1%	$233K+1564.3%	$14K+27.3%	$11K
Financing Cash Flow	$7.0M	N/A	-$865K	N/A	-$1.7M-145.8%	$3.7M+157.0%	$1.4M+119.0%	-$7.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ELOX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-38.8%	N/A	N/A	N/A	N/A
Net Margin	N/A	-49.4%	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-298.1%+39.9pp	-338.0%
Return on Assets	-113.8%-8.1pp	-105.6%	N/A	-170.7%-22.9pp	-147.8%-17.2pp	-130.6%
Current Ratio	0.31+0.2	0.11+0.0	0.07-0.8	0.87-3.5	4.37+1.7	2.63
Debt-to-Equity	0.000.0	0.00+0.1	-0.07+0.7	-0.80-1.3	0.54-0.1	0.62
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q4'23	Q3'23	Q2'23	Q1'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-38.2%
Return on Assets	-44.1%	N/A	N/A	N/A	N/A	-59.5%+13.0pp	-72.4%+14.1pp	-86.5%
Current Ratio	0.53+0.2	0.31	N/A	0.11+0.0	0.07-0.2	0.24-0.0	0.25-0.1	0.33
Debt-to-Equity	-2.12-2.1	0.00	N/A	0.00+0.1	-0.07+0.1	-0.13+0.0	-0.18-0.4	0.25
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$11.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Regenerx Biopharmaceuticals RGRX

$299

Neximmune, Inc. NEXI

$4.1M

Effector Therapeutics Inc EFTR

$612K

Gritstone Bio Inc GRTSQ

$1K

Innoveren Scientific Inc IVRN

$932

Frequently Asked Questions

What is Eloxx Pharmaceut's annual revenue?

Eloxx Pharmaceut (ELOX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Eloxx Pharmaceut's revenue growing?

Eloxx Pharmaceut (ELOX) revenue declined by 100% year-over-year, from $6.4M to $0 in fiscal year 2025.

Is Eloxx Pharmaceut profitable?

No, Eloxx Pharmaceut (ELOX) reported a net income of -$6.0M in fiscal year 2025.

What is Eloxx Pharmaceut's EBITDA?

Eloxx Pharmaceut (ELOX) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Eloxx Pharmaceut have?

As of fiscal year 2025, Eloxx Pharmaceut (ELOX) had $4.8M in cash and equivalents against $0 in long-term debt.

What is Eloxx Pharmaceut's operating cash flow?

Eloxx Pharmaceut (ELOX) generated -$6.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Eloxx Pharmaceut's total assets?

Eloxx Pharmaceut (ELOX) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Eloxx Pharmaceut spend on research and development?

Eloxx Pharmaceut (ELOX) invested $3.1M in research and development during fiscal year 2025.

How many shares does Eloxx Pharmaceut have outstanding?

Eloxx Pharmaceut (ELOX) had 435,432 shares outstanding as of fiscal year 2025.

What is Eloxx Pharmaceut's current ratio?

Eloxx Pharmaceut (ELOX) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Eloxx Pharmaceut's debt-to-equity ratio?

Eloxx Pharmaceut (ELOX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Eloxx Pharmaceut's return on assets (ROA)?

Eloxx Pharmaceut (ELOX) had a return on assets of -113.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Eloxx Pharmaceut's cash runway?

Based on fiscal year 2025 data, Eloxx Pharmaceut (ELOX) had $4.8M in cash against an annual operating cash burn of $6.3M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Eloxx Pharmaceut's debt-to-equity ratio negative or unusual?

Eloxx Pharmaceut (ELOX) has negative shareholder equity of -$11.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Eloxx Pharmaceut's Altman Z-Score?

Eloxx Pharmaceut (ELOX) has an Altman Z-Score of -85.15, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Eloxx Pharmaceut's Piotroski F-Score?

Eloxx Pharmaceut (ELOX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Eloxx Pharmaceut's earnings high quality?

Eloxx Pharmaceut (ELOX) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.